Jun Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Ye has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Ji Yuan
Department of Infectious Diseases, The Second Hospital of Anhui Medical University, Hefei, People’s Republic of China
2 shared publicationsJinjin Li
Department of Infectious Diseases, The Second Hospital of Anhui Medical University, Hefei, People’s Republic of China
2 shared publicationsChangkang Chen
Department of Infectious Diseases, The Second Hospital of Anhui Medical University, Hefei, Anhui, China
1 shared publicationCheng Yao
Frontier Biotechnologies Inc
1 shared publication- Cheng Yao
Frontier Biotechnologies Inc, Nanjing, China
1 shared publication Dong Xie
Frontier Biotechnologies Inc
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Human herpesvirus-6B infection leading to hemophagocytic lymphohistiocytosis in an adult: a case report
Hemophagocytic lymphohistiocytosis (HLH) secondary to human herpesvirus-6B (HHV-6B) infection is rare in immunocompetent adults. We report the case of a 43
- 6 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessHuman herpesvirus-6B infection leading to hemophagocytic lymphohistiocytosis in an adult: a case report
Hemophagocytic lymphohistiocytosis (HLH) secondary to human herpesvirus-6B (HHV-6B) infection is rare in immunocompetent adults. We report the case of a 43
- Open Access
- 29 January 2026
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 59 (4) , 517-520
A case of avian influenza A (H5N6) presented with secondary infection in Anhui Province, China, 2024
- 29 January 2026
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 59 (4) , 517-520
Open AccessA case of avian influenza A (H5N6) presented with secondary infection in Anhui Province, China, 2024
- Open Access
- 28 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1540430
Fusobacterium nucleatum infection leading to rare hepatorenal abscess: a case report
Fusobacterium nucleatum is a gram-negative anaerobic bacterium commonly associated with periodontal disease. However, its role in extraoral infections, particularly in immunocompetent individuals, is increasingly recognized. We report a rare case of hepatorenal abscess caused by F. nucleatum in a previously healthy woman, initially suspected to have a malignant tumor based on PET-CT findings. Next-generation sequencing (NGS) of abscess aspirate confirmed the pathogen. The patient responded well to targeted antibiotic therapy. This case highlights the importance of considering anaerobic pathogens in deep-seated abscesses and the utility of NGS in achieving accurate microbial diagnosis.
- 28 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1540430
Open AccessFusobacterium nucleatum infection leading to rare hepatorenal abscess: a case report
Fusobacterium nucleatum is a gram-negative anaerobic bacterium commonly associated with periodontal disease. However, its role in extraoral infections, particularly in immunocompetent individuals, is increasingly recognized. We report a rare case of hepatorenal abscess caused by F. nucleatum in a previously healthy woman, initially suspected to have a malignant tumor based on PET-CT findings. Next-generation sequencing (NGS) of abscess aspirate confirmed the pathogen. The patient responded well to targeted antibiotic therapy. This case highlights the importance of considering anaerobic pathogens in deep-seated abscesses and the utility of NGS in achieving accurate microbial diagnosis.
- 3 August 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (2) , 913-922
Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics (PK), tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. Thirty subjects were randomly divided into three groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose of 320 mg ABT either by intravenous drip for 45 min (group A) or bolus injection for 0.5 min (group B), or bolus injection for 3 min (group C). ABT plasma concentrations were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Non-compartmental analysis was used to evaluate PK parameters. The median time to reach maximum concentration was 0.75 h in group A and 0.16 h in both groups B and C. Elimination half-life, mean residence time, apparent clearance, and apparent volume of distribution were similar among the three groups. The 90% confidence intervals (CI) of geometric mean ratios of PK parameters for groups B and C relative to group C were within 85–120%. All adverse events (AEs) reported in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement. ABT bolus injections for 0.5 min and 3 min are expected to be well tolerated and to exhibit similar PK characteristics as IV drip for 45 min, offering potential clinical benefits.
- 3 August 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (2) , 913-922
Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics (PK), tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. Thirty subjects were randomly divided into three groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose of 320 mg ABT either by intravenous drip for 45 min (group A) or bolus injection for 0.5 min (group B), or bolus injection for 3 min (group C). ABT plasma concentrations were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Non-compartmental analysis was used to evaluate PK parameters. The median time to reach maximum concentration was 0.75 h in group A and 0.16 h in both groups B and C. Elimination half-life, mean residence time, apparent clearance, and apparent volume of distribution were similar among the three groups. The 90% confidence intervals (CI) of geometric mean ratios of PK parameters for groups B and C relative to group C were within 85–120%. All adverse events (AEs) reported in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement. ABT bolus injections for 0.5 min and 3 min are expected to be well tolerated and to exhibit similar PK characteristics as IV drip for 45 min, offering potential clinical benefits.
- Open Access
- 24 April 2023
- Published by Springer Nature in Research Square
Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
Purpose. Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor originally developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics, tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects.Methods. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. 30 subjects were randomly divided into 3 groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose administration of 320 mg ABT by intravenous drip for 45 min (Group A) or bolus injection for 0.5 min (Group B) or bolus injection for 3 min (Group C). ABT plasma concentrations were analyzed using validated enzyme-linked immunosorbent assay. Noncompartmental analysis was used to evaluate PK parameters.Results. The median value of time to reach maximum concentration was 0.75 h in group A and 0.16 h in both group B and C, elimination half-life, mean residence time, apparent clearance and apparent volume of distribution was similar among three groups. The 90% confidence intervals of geometric mean ratios of PK parameters for group B and C relative to group C are mainly within 85–120%. All AEs in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement.Conclusion. ABT bolus injection for 0.5 min and 3 min are expected well tolerated and to have similar pharmacokinetic characteristics as IV drip for 45 min, thus offering potential clinical benefits.
- 24 April 2023
- Published by Springer Nature in Research Square
Open AccessComparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
Purpose. Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor originally developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics, tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects.Methods. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. 30 subjects were randomly divided into 3 groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose administration of 320 mg ABT by intravenous drip for 45 min (Group A) or bolus injection for 0.5 min (Group B) or bolus injection for 3 min (Group C). ABT plasma concentrations were analyzed using validated enzyme-linked immunosorbent assay. Noncompartmental analysis was used to evaluate PK parameters.Results. The median value of time to reach maximum concentration was 0.75 h in group A and 0.16 h in both group B and C, elimination half-life, mean residence time, apparent clearance and apparent volume of distribution was similar among three groups. The 90% confidence intervals of geometric mean ratios of PK parameters for group B and C relative to group C are mainly within 85–120%. All AEs in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement.Conclusion. ABT bolus injection for 0.5 min and 3 min are expected well tolerated and to have similar pharmacokinetic characteristics as IV drip for 45 min, thus offering potential clinical benefits.